In adults, approved indications for growth hormone therapy include childhood-onset growth hormone deficiency, adult-onset hypopituitarism (underactive pituitary gland) due to pituitary or hypothalamic disease, AIDS-related wasting syndrome, and short bowel syndrome (18, 19)
"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide"
Switching to alternative delivery methods For researchers who find the entire syringe process burdensome, alternative delivery methods eliminate the question entirely
This spike in attention is filling the pockets of the medications Danish manufacturer Novo Nordisk, who pocketed $3.4bn in 2020 alone, and are projected to make $7.8bn by 2023 - particularly as use of Ozempic in the UK soars
The demographic and clinical characteristics of all ICSRs are outlined in Table 2